Overview

A Study of Cardiovascular Events iN Diabetes Plus

Status:
Not yet recruiting
Trial end date:
2048-08-17
Target enrollment:
Participant gender:
Summary
ASCEND PLUS is testing whether, for people with type 2 diabetes who have not previously had a heart attack or stroke, regularly taking a tablet called semaglutide can safely help to reduce heart attacks, strokes, mini-strokes, the need for any procedures to unblock or bypass an artery to their heart, and the chance of dying because of vascular problems.
Phase:
Phase 4
Details
Lead Sponsor:
University of Oxford
Collaborator:
Novo Nordisk A/S